Drug Profile
Interferon beta gene therapy - Biogen Idec/Targeted Genetics
Alternative Names: Ad-beta-Ifn; Ad.hIFN-beta; Adenoviral-mediated Interferon-beta; Beta-interferon gene therapy - Biogen Idec/Targeted Genetics; BG 00001; IDEC-201Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Biogen Idec; Targeted Genetics
- Developer Biogen; Biogen Idec; Targeted Genetics Corporation
- Class Antineoplastics; Gene therapies; Immunotherapies; Interferons
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma; Mesothelioma
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 24 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Cancer pharmacodynamics section
- 03 Mar 2004 A preclinical study has been added to the Cancer pharmacodynamics section